Overview

A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

Status:
Terminated
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the possibility that use of two similar but distinct drugs used together in treatment of advanced cancer might prove less toxic than either agent used alone, because dosages can be reduced for each agent. This is a phase I study that is designed to measure the frequency and levels of specific side effects when Carboplatin and Pazopanib are used in combination in advanced cancer patients. The possibility that anti-tumor activity will occur is also going to be investigated.
Phase:
Phase 1
Details
Lead Sponsor:
New Mexico Cancer Care Alliance
Collaborator:
GlaxoSmithKline
Treatments:
Carboplatin